What's New
v0.1.2 · 2026-05-31 — the biggest update yet. CatalystAlert is in beta; tell us what to improve via the feedback button on any page.
Now: a 7-day free trial
Pro starts with 7 days of full access — no charge until it ends, cancel anytime.
New
- •Catalyst Verdict — one synthesized read per catalyst: clinical success odds (LOA), expected move, and the pre-catalyst run-up.
- •Market-Implied Move — what the options market is pricing for a catalyst (for names with listed options).
- •Opportunities, rebuilt — pre-catalyst run-up setups ranked by a transparent conviction score.
- •Compare pages — honest "CatalystAlert vs …" comparisons and a Best biotech catalyst tools roundup.
- •Public prediction track record — split into two honest tracks: Impact (event-day) and Entry-timing (run-up).
Smarter, more honest predictions
- •New ML models: LOA v3, Impact v4, and Entry "run-up conviction" v3, calibrated to the recent market regime.
- •Entry predictions are now graded against the actual pre-catalyst run-up — the correct yardstick.
Trustworthy dates
- •Every catalyst date carries a confidence label — confirmed (official source), estimated, or AI-detected.
- •Source links, "updated" freshness signals, automatic cross-source verification, and de-duplication.
Data & experience
- •Scrubbable, mobile-first stock chart with volume bars.
- •Mobile layout polish across company and drug pages.
- •New logo and icons; calendar de-cluttered and ranked by signal; broader IPO and international coverage.
Trust & transparency
- •Calmer, factual copy — informational only, never financial advice, no gain-promises.
- •Clear data sourcing (FDA, SEC EDGAR, ClinicalTrials.gov) and visible disclaimers.
CatalystAlert is in beta. Informational only — not financial advice. Always confirm a date against its official source before trading.